• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

慢性阻塞性肺疾病的全身影响

Systemic effects of chronic obstructive pulmonary disease.

作者信息

Agustí Alvar G N

机构信息

Servei Pneumología, Hospital Universitario Son Dureta, Andrea Doria 55, 07014 Palma Mallorca, Spain.

出版信息

Proc Am Thorac Soc. 2005;2(4):367-70; discussion 371-2. doi: 10.1513/pats.200504-026SR.

DOI:10.1513/pats.200504-026SR
PMID:16267364
Abstract

Chronic obstructive pulmonary disease (COPD) affects various structural and functional domains in the lungs. It also has significant extrapulmonary effects, the so-called systemic effects of COPD. Weight loss, nutritional abnormalities, and skeletal muscle dysfunction are well-recognized systemic effects of COPD. Other less well-known but potentially important systemic effects include an increased risk of cardiovascular disease and several neurologic and skeletal defects. The mechanisms underlying these systemic effects are unclear, but they are probably interrelated and multifactorial, including inactivity, systemic inflammation, tissue hypoxia and oxidative stress among others. These systemic effects add to the respiratory morbidity produced by the underlying pulmonary disease and should be considered in the clinical assessment as well as the treatment of affected patients.

摘要

慢性阻塞性肺疾病(COPD)会影响肺部的各种结构和功能区域。它还具有显著的肺外效应,即所谓的COPD全身效应。体重减轻、营养异常和骨骼肌功能障碍是COPD公认的全身效应。其他不太为人所知但可能很重要的全身效应包括心血管疾病风险增加以及一些神经和骨骼缺陷。这些全身效应的潜在机制尚不清楚,但它们可能相互关联且是多因素的,包括缺乏运动、全身炎症、组织缺氧和氧化应激等。这些全身效应会加重潜在肺部疾病所导致的呼吸发病率,在对受影响患者的临床评估和治疗中都应予以考虑。

相似文献

1
Systemic effects of chronic obstructive pulmonary disease.慢性阻塞性肺疾病的全身影响
Proc Am Thorac Soc. 2005;2(4):367-70; discussion 371-2. doi: 10.1513/pats.200504-026SR.
2
Systemic effects of chronic obstructive pulmonary disease.慢性阻塞性肺疾病的全身影响
Eur Respir J. 2003 Feb;21(2):347-60. doi: 10.1183/09031936.03.00405703.
3
COPD recent findings: impact on clinical practice.COPD 最新研究进展:对临床实践的影响。
COPD. 2010 Jun;7(3):204-13. doi: 10.3109/15412555.2010.482115.
4
COPD as a systemic disease.慢性阻塞性肺疾病作为一种全身性疾病。
COPD. 2008 Apr;5(2):133-8. doi: 10.1080/15412550801941349.
5
[Peripheral muscle dysfunction in chronic obstructive pulmonary disease].[慢性阻塞性肺疾病中的外周肌肉功能障碍]
Pneumologia. 2012 Jul-Sep;61(3):178-82.
6
Systemic effects of chronic obstructive pulmonary disease.慢性阻塞性肺疾病的全身效应。
Expert Rev Respir Med. 2007 Aug;1(1):75-84. doi: 10.1586/17476348.1.1.75.
7
Comorbidities and systemic effects of chronic obstructive pulmonary disease.慢性阻塞性肺疾病的合并症及全身影响。
Clin Chest Med. 2014 Mar;35(1):101-30. doi: 10.1016/j.ccm.2013.10.007.
8
Systemic inflammation and skeletal muscle dysfunction in chronic obstructive pulmonary disease: state of the art and novel insights in regulation of muscle plasticity.慢性阻塞性肺疾病中的全身炎症与骨骼肌功能障碍:肌肉可塑性调节的最新进展与新见解
Clin Chest Med. 2007 Sep;28(3):537-52, vi. doi: 10.1016/j.ccm.2007.06.003.
9
COPD: a multifactorial systemic disease.COPD:一种多因素的系统性疾病。
Ther Adv Respir Dis. 2011 Jun;5(3):217-24. doi: 10.1177/1753465811400490. Epub 2011 Mar 23.
10
Markers of systemic involvement in chronic obstructive pulmonary disease.慢性阻塞性肺疾病全身受累的标志物。
Rom J Intern Med. 2012 Apr-Jun;50(2):129-34.

引用本文的文献

1
Evaluation of Prothrombotic Biomarkers in Stable and Exacerbation Phases of Chronic Obstructive Pulmonary Disease: A Case-Control Study.慢性阻塞性肺疾病稳定期和加重期的血栓前生物标志物评估:一项病例对照研究。
Cureus. 2025 Aug 6;17(8):e89469. doi: 10.7759/cureus.89469. eCollection 2025 Aug.
2
Association between impaired lung function and risk of spondyloarthritis: a cross-sectional study in the UK Biobank.肺功能受损与脊柱关节炎风险之间的关联:英国生物银行的一项横断面研究
Ther Adv Musculoskelet Dis. 2025 Sep 1;17:1759720X251371112. doi: 10.1177/1759720X251371112. eCollection 2025.
3
Efficacy and safety of physical therapy in patients with stage III COPD during ambulatory rehabilitation.
III 期 COPD 患者在门诊康复期间的物理治疗的疗效和安全性。
J Med Life. 2023 Dec;16(12):1769-1775. doi: 10.25122/jml-2023-0237.
4
Inspiratory versus expiratory incentive spirometry: A randomised control trial study protocol.吸气式与呼气式激励肺活量测定法:一项随机对照试验研究方案。
S Afr J Physiother. 2023 Oct 9;79(1):1841. doi: 10.4102/sajp.v79i1.1841. eCollection 2023.
5
[Could Inspiratory Muscle Function Be an Equivalent of Lung Hyperinflation in COPD Patients?].[吸气肌功能能否等同于慢性阻塞性肺疾病患者的肺过度充气?]
Open Respir Arch. 2021 Feb 20;3(1):100084. doi: 10.1016/j.opresp.2021.100084. eCollection 2021 Jan-Mar.
6
Prevalence of and factors associated with alexithymia among patients with chronic obstructive pulmonary disease in China: a cross-sectional study.中国慢性阻塞性肺疾病患者的述情障碍患病率及相关因素:一项横断面研究。
BMC Pulm Med. 2023 Jan 30;23(1):40. doi: 10.1186/s12890-023-02335-5.
7
Inspiratory muscle training, with or without concomitant pulmonary rehabilitation, for chronic obstructive pulmonary disease (COPD).吸气肌训练,联合或不联合肺康复治疗,用于慢性阻塞性肺疾病(COPD)。
Cochrane Database Syst Rev. 2023 Jan 6;1(1):CD013778. doi: 10.1002/14651858.CD013778.pub2.
8
Emerging phenotypes of pulmonary hypertension associated with COPD: a field guide.COPD 相关肺动脉高压的新兴表型:实用指南。
Curr Opin Pulm Med. 2022 Sep 1;28(5):343-351. doi: 10.1097/MCP.0000000000000890. Epub 2022 Jul 16.
9
Association of chronic inflammation with cardiovascular risk in chronic obstructive pulmonary disease-A cross-sectional study.慢性阻塞性肺疾病中慢性炎症与心血管风险的关联——一项横断面研究
Health Sci Rep. 2022 Apr 7;5(3):e586. doi: 10.1002/hsr2.586. eCollection 2022 Apr.
10
Therapeutic Success in Swiss COPD Patients Receiving Dual Bronchodilation Therapy as COPD Maintenance Treatment.瑞士慢性阻塞性肺疾病(COPD)患者接受双重支气管扩张治疗作为COPD维持治疗的治疗成功情况。
Clin Pract. 2022 Jan 7;12(1):46-56. doi: 10.3390/clinpract12010006.